Please login to the form below

lenalidomide

This page shows the latest lenalidomide news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

Celgene has had a difficult few months, with the latest knock coming after its blood cancer blockbuster Revlimid (lenalidomide) failed to hit the mark in non-Hodgkin’s lymphoma, the failure

Latest news

Amgen set for Kyprolis label boost after CHMP backing

Currently, Kyprolis is approved in the EU for us in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have
Celgene reaches $9bn agreement to buy Juno

Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation
Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

Last year, NICE said it was unable to make a recommendation about use of Darzalex in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone for relapsed and refractory myeloma because Janssen
Is acquisitive Celgene now eyeing CAR-T specialist Juno?

lenalidomide) with Juno’s CAR-T candidates.
Celgene gains French reimbursement for Revlimid in multiple myeloma

Patients in France will soon be able to access Celgene’s Revlimid (lenalidomide) for two cancer indications following a decision to reimburse the drug by the French National Authority for

More from news
Approximately 14 fully matching, plus 73 partially matching documents found.

Latest Intelligence

Building a business that is lean and specialised

drug Revlimid (lenalidomide).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Scientific Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Medical Writer: Great salary and bebefits

Project Manager, Medical Communications, Oxford: Excellent Salary

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Account Manager – Med Comms – London: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor – Medical Education Agency – Bucks: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Medical Writer, e-learning/ training, London: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer: Great salary and benefits

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...